Viking Therapeutics (Viking Therapeutics) EBIT per Share : $-1.13 (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Viking Therapeutics EBIT per Share?

Viking Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was $-0.33. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.13.

During the past 3 years, the average EBIT per Share Growth Rate was -22.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was -20.70% per year. During the past 10 years, the average EBIT per Share Growth Rate was -7.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Viking Therapeutics's EBIT per Share or its related term are showing as below:

VKTX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -233.2 Med: -4.8 Max: 48.7
Current: -22

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Viking Therapeutics was 48.70% per year. The lowest was -233.20% per year. And the median was -4.80% per year.

VKTX's 3-Year EBIT Growth Rate is ranked worse than
75.86% of 1305 companies
in the Biotechnology industry
Industry Median: 3.4 vs VKTX: -22.00

Viking Therapeutics's EBIT for the three months ended in Mar. 2024 was $-34.07 Mil.

Viking Therapeutics EBIT per Share Historical Data

The historical data trend for Viking Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viking Therapeutics EBIT per Share Chart

Viking Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.45

-0.59

-0.72

-0.92

-1.07

Viking Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.26	-0.24	-0.27	-0.29	-0.33

Viking Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Viking Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-100.827	/	94.347
=	-1.07

Viking Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-34.073	/	103.457
=	-0.33

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.13

Viking Therapeutics (NAS:VKTX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Viking Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Viking Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Viking Therapeutics (Viking Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viking Therapeutics Inc (NAS:VKTX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

1VT:Germany 1VT:Germany

Address

9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121

Website

https://www.vikingtherapeutics.com

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Executives

Sarah Kathryn Rouan	director	4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017
Greg Zante	officer: Chief Financial Officer	C/O SANGAMO BIOSCIENCES, INC STE-A-100, POINT RICHMOND TECH, 501 CANAL BLVD,, RICHMOND CA 94804
Rowland Charles A Jr	director	3338 LANCASHIRE RD, FURLONG PA 18925
Lawson Macartney	director	C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Brian Lian	director, officer: President & CEO	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Marianna Mancini	officer: Chief Operating Officer	C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, STE 250, SAN DIEGO CA 92130
Matthew W Foehr	director	11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Ligand Pharmaceuticals Inc	10 percent owner	3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Hiroko Masamune	officer: Chief Development Officer	C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Michael Morneau	officer: Chief Financial Officer	C/O TRIUS THERAPEUTICS, INC., 6410 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
J Matthew Singleton	director	286 STANWICH ROAD, GREENWICH CT 06830
Stephen W Webster	director	C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Rochelle Hanley	officer: Chief Medical Officer	C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037
Michael Dinerman	officer: Chief Operating Officer	C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037